Thesis

Precision BioSciences is trading at cash value. The market is pricing the entire pipeline — two wholly-owned clinical programs, multiple partnership royalty streams, and PRV optionality worth more than the company — at somewhere between $9M and $24M. That's an implied ≈13% probability of success on the lead HBV program. Our estimate is 45%. Either we're wrong, or the market is giving away free options on a validated gene editing platform with data dropping in three months.

This isn't a "cheap biotech" thesis. It's a specific claim: the market has collapsed the probability distribution on DTIL to near-zero, and cross-ticker evidence says the distribution should be wider. The HBV program is the only clinical-stage in vivo gene editor targeting cccDNA — confirmed across BEAM, NTLA, CRSP, and VERV, none of whom have an HBV program. The DMD program holds every regulatory designation available (RPD, Orphan, Fast-Track, PRV-eligible) and enters a competitive landscape that just cleared out: Sarepta's ESSENCE trial failed, Elevidys got a black box warning for fatal liver injuries, PTC withdrew Translarna.

The question is not whether this is interesting. It is. The question is whether we can size it honestly given what we know and don't know.

The Numbers

Balance sheet (12/31/2025):

• Cash: $110.8M unrestricted + $26.3M restricted (collateralizing $22.4M term loan)
• TG Therapeutics milestone: $7.5M received March 2026
• Burn: $65.8M/year operating cash usage
• Debt: $22.4M (fully collateralized, not a credit concern)
• Shares: 24.7M outstanding + 6.1M warrants at $7.25

The cash per share is $4.79 unrestricted, $4.95 net. Stock trades at $5.15. You're paying $0.20-0.36 per share for the pipeline. The cash floor is eroding at ≈$2.67/share/year from burn, so this optionality has time decay — but not fatal time decay with runway stated through 2028.

Revenue is misleading in both directions. FY2025 was $34M, but $26.3M was non-recurring Novartis deferred revenue recognized on termination and $8M was an Imugene milestone. FY2024 was $69M, but $52.7M was Prevail conclusion revenue. Run-rate for FY2026 is ≈$7.5M (TG milestone) plus whatever new deals emerge. The revenue line is decoration. Focus on the operating cash burn: $65.8M/year, trending down slightly as the company paused PBGENE-3243 and cut G&A from $35M to $32M.

Dilution has been severe. Shares went from 8.2M to 24.7M in 15 months — 200%+ increase. The November 2025 offering ($75M gross at $6.14/share) bought the runway extension but crushed per-share metrics. The 6.1M warrants at $7.25 are classified as derivative liabilities (ASC 815) because of a cash settlement clause in M&A scenarios. This creates GAAP noise every quarter — the Q4 2025 EPS "beat" ($1.01 vs -$0.64 estimate) was driven almost entirely by warrant fair value gains, not operational improvement.

R&D spending confirms stated priorities. PBGENE-DMD external spend went from $1.2M to $15.3M (12x YoY). HBV dropped from $16.1M to $7.2M as it transitioned from manufacturing/toxicology to clinical operations. PBGENE-3243 dropped from $9.8M to $3.1M (paused). Money is going where management says it's going.

The HBV Program — Why It Matters

PBGENE-HBV is the primary value driver. The AASLD presentation (November 2025) showed: 9 patients, 22 doses across 3 cohorts (0.2/0.4/0.8 mg/kg at 8-week intervals), zero dose-limiting toxicities, cumulative dose-dependent antiviral activity, HBsAg declines, and — critically — paired biopsy data showing first evidence consistent with direct viral DNA gene editing.

This is not incremental. No prior in vivo gene editor had demonstrated repeat LNP administration safety at this scale (30+ administrations across 5 cohorts), and no one had shown biopsy evidence of cccDNA editing in HBV patients. The mechanism works. The question is whether it works well enough.

We confirmed "first and only" across the gene editing landscape. BEAM is focused on AATD and Pfizer LNP partnerships. Intellia is in ATTR and AATD (and dealing with a clinical hold on MAGNITUDE after a patient death). CRISPR Therapeutics is in cardiovascular gene editing. Verve is in PCSK9/ANGPTL3. Nobody else is in clinical-stage HBV cccDNA editing.

The complication is GSK/Ionis bepirovirsen, which hit positive Phase 3 results in January 2026 — statistically significant functional cure rate in 1,800+ patients, first fixed-course ASO therapy for chronic HBV. If approved (regulatory filings planned Q1 2026), bepirovirsen captures the broad HBV market before gene editing gets there. But bepirovirsen suppresses HBsAg (functional cure); DTIL destroys cccDNA (mechanistic cure). Patients who relapse after bepirovirsen are the addressable market for gene editing. These are different mechanisms addressing different clinical needs.

H1 2026 biopsy data is the near-term catalyst. If cccDNA reduction is quantifiable and HBsAg suppression is accelerating at optimized dose intervals — the stock re-rates. If efficacy plateaus at higher doses — the bear case wins.

The DMD Program — PRV Math

PBGENE-DMD cleared IND in February 2026. It holds Rare Pediatric Disease designation (June 2025), Orphan Drug (July 2025), and Fast-Track (February 2026). It's eligible for a Priority Review Voucher upon approval.

PRV pricing has risen sharply: $103M (Valneva, Feb 2024) to $205M (Cyprium/Fortress, Feb 2026). The RPD program sunset is driving scarcity pricing. At current market prices, a PRV is worth $150-205M. DTIL's own 10-K estimates $100-150M — conservative relative to the last transaction.

At a $127M market cap with $118M net cash, the entire company trades for less than a single PRV. This is PRV optionality at zero cost — you'd need to believe there is literally no probability of DMD approval for this to be fairly priced.

The DMD competitive landscape is favorable. Sarepta's ESSENCE trial missed its primary endpoint (p=0.309). Elevidys received a black box warning for fatal liver injuries. PTC withdrew Translarna. RGNX (RGX-202) is the most advanced competitor with pivotal data expected Q2 2026, but delivers microdystrophin vs DTIL's near-full-length dystrophin. Scientific literature validates the superiority of near-full-length approaches — midi-dystrophin showed "far greater phenotypic correction than microdystrophin" in preclinical studies, and two microdystrophins caused "lethal acceleration of cardiac disease" in animal models.

DTIL is early — just cleared IND, first patient data year-end 2026. But the approach is differentiated and the competitive field is thinning.

The Bear Case — Novartis Walked

Novartis terminated its hemoglobinopathies collaboration without cause in October 2025. They paid $50M upfront, spent three years with the ARCUS platform, and left. This is the single most important negative signal in the filing.

The charitable read: Novartis is portfolio rebalancing. Casgevy (CRISPR/Vertex) was approved in December 2023 for SCD, making Novartis's in vivo gene editing approach less competitive. Novartis also dropped an Intellia SCD program in 2023. They acquired Kate Therapeutics ($1.1B, November 2024) for capsid engineering — a shift toward next-gen AAV delivery rather than nuclease editing. And the continued undisclosed ARCUS collaboration suggests Novartis didn't reject the platform broadly.

The concerning read: A sophisticated pharma partner with $50M invested looked at ARCUS for three years and walked. That's an informed party making a negative decision. The "undisclosed collaboration" could be a courtesy arrangement, not a signal of continued conviction.

We can't fully resolve this. Circumstantial evidence favors portfolio rebalancing over ARCUS-specific rejection, but the uncertainty is real.

Factor Decomposition

Statistical regression (251 trading days): 83.7% idiosyncratic variance, 17.9% XBI exposure (β=1.14), negligible SPY and momentum contribution. Passes the 75% idio threshold — returns are driven by company-specific events, not biotech sector.

The recent +37% monthly move happened while XBI was down 2.8%. This is genuinely idiosyncratic signal, not beta.

Economic decomposition — where the value lives:

Edge% = 33%. The thesis is 65% concentrated in two binary clinical outcomes where we see the setup but can't predict the biology. Our edge is in recognizing the asymmetry (pipeline at zero, PRV > market cap, competitive clearing), not in forecasting clinical results.

Entry and Forward EV

The market implies ≈13% probability of HBV success. Our estimate is 45%. The 32-percentage-point gap is the thesis.

Scenario-weighted EV at current scenario probabilities (bull $18 at 20%, base $5 at 50%, bear $2 at 30%): $6.70, or 30% upside from $5.15. Adjusting for our HBV probability mapping (P(bull) ≈ 22.5%): $7.08, or 37.5% upside.

But at 33% Edge% and doorway-state conviction, adjusted alpha is only 5.4% annualized at $5.15 entry. Marginal.

At a $4.00 entry (50DMA pullback): adjusted alpha triples to 12.0%. The entry price matters more than the scenario probabilities for a 64% idio vol name.

Current price is in the WAIT zone. RSI at 75.8, +37% in a month, max pain at $2.50. Insiders are net selling (RSU vest sales, not alarming but not bullish). The preferred entry is $3.75-4.25 — near the 50DMA and below cash per share, where the pipeline is literally free.

The ideal sequence: wait for post-KOL (March 17) or XBI-driven pullback, enter at $3.75-4.25, then add meaningful exposure if H1 2026 HBV data is positive — at that point Edge% jumps from 33% to 55%+ and the thesis becomes a conviction position, not an optionality bet.

What We Don't Know

1. Quantitative HBsAg/HBV DNA reductions from the AASLD presentation. The 10-K says "substantial" — the actual numbers determine whether H1 2026 is a catalyst or a disappointment.

2. Bepirovirsen relapse rates. If GSK's functional cure is durable in most patients, the addressable market for cccDNA editing shrinks materially.

3. Why Novartis really left. Circumstantial evidence favors portfolio rebalancing, but we lack definitive confirmation.

4. iECURE financial health. The royalty stream depends on a private company staying funded through BLA.

Conclusion

This is a real setup. Pipeline at zero, first-and-only in clinical cccDNA editing, PRV optionality worth more than the market cap, competitive landscape clearing in DMD, autoimmune CAR T wave validated by Kyverna's registrational success and BMS's entry. Cross-ticker corroboration confirmed all three bullish signals. The asymmetry is genuine.

But don't mistake seeing the setup for having edge on the outcome. 65% of the value depends on binary clinical results we can't predict. Novartis walked. Dilution has been brutal. The stock just ran 37% in a month. Entry at $5.15 gives you 5.4% adjusted alpha — not enough for a 64% vol name.

Watch for a pullback to $3.75-4.25 to establish an optionality position. If HBV data drops positive in H1 2026, the edge doubles and the thesis becomes a conviction trade — the setup is materially different after positive data. If HBV data is negative, the thesis is invalidated.

The positioning window is March through May. After that, the doorway collapses one way or the other.

Evidence